Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Changing the course of Alzheimer s disease: anti-amyloid disease-modifying treatments on the horizon Christensen DDPrim Care Companion J Clin Psychiatry 2007[]; 9 (1): 32-41OBJECTIVES: To review the amyloid hypothesis as the predominant mechanistic theory of Alzheimer's disease and update the status of new disease-modifying, anti-amyloid treatments in clinical development. DATA SOURCES: Governmental Web sites and those of professional Alzheimer's disease associations and drug manufacturers were searched for new drugs in development. An English-language search of PubMed (January 2003-January 2006) was conducted using the search terms Alzheimer's disease and amyloid hypothesis and each of the drugs and immunotherapies from the 4 identified classes of anti-amyloid, disease-modifying therapies. STUDY SELECTION AND DATA EXTRACTION: Studies and reports were selected on the basis of recent publication, adequate methodology, and completeness of data. DATA SYNTHESIS: Immunotherapy, gamma-secretase inhibitors, selective neurotoxic aggregated 42-amino acid peptide subspecies of amyloid beta (Abeta(4)(2))-lowering agents (tarenflurbil), inhibitors of amyloid aggregation (tramiprosate), and statins show promise in clinical trials. Safety remains an important factor. Disease-modifying drugs that specifically target the amyloid cascade and do not interact with essential biological pathways are expected to possess a lower rate of unintended adverse events.Agents that selectively target Abeta(4)(2) production (e.g., tarenflurbil), block Abeta aggregation (e.g., tramiprosate), or enhance alpha-secretase activity (statins) offer hope for disease modification and prevention and do not appear to interfere with other biological pathways. CONCLUSIONS: Discovery of safe and effective disease-modifying therapies will usher in a new age of Alzheimer's disease treatment.ä |